KARO BIO AND WYETH COLLABORATION - TARGETS INFLAMMATION

KARO BIO AND WYETH COLLABORATION - TARGETS INFLAMMATION

Karo Bio and Wyeth Pharmaceuticals have a drug discovery collaboration with the
liver X receptor (LXR) as pharmaceutical target. LXR is a new member of the
nuclear receptor protein family and the receptor plays important roles in
cholesterol metabolism and inflammatory responses. The collaboration with Wyeth
has primarily been focused on atherosclerosis but other clinical opportunities
have also been explored. The continued collaboration will focus on drug
discovery in the field of inflammatory diseases."Our collaboration with Wyeth has generated numerous compound series and a
deepened understanding about LXR function in disease processes. Recently is has
been shown that LXR is an important target for treatment of inflammatory
disorders and we see exciting opportunities in the continued collaboration" says
Per Olof Wallström, President of Karo Bio.

For further information, please contact:
Per Olof Wallström, President & Chief Executive Officer 
Phone: +46 8 608 60 20

Per Otteskog, Senior Vice President 
Phone: +46 8 608 60 18


About Karo Bio 
Karo Bio is a drug discovery and development company specializing in nuclear
receptors for the development of novel pharmaceuticals. 

The Company has a project portfolio with innovative molecules that primarily
targets metabolic diseases such as diabetes, atherosclerosis and dyslipidemia.
In all of these areas there are significant market opportunities and a need for
new pharmaceuticals with new mechanisms of action. Karo Bio intends to bring
selected compounds within niche therapeutic areas into late stage clinical
development and, potentially, to the market. In addition to pursuing niche
opportunities, Karo Bio continues to develop compounds aimed at treatment of
broad patient populations to clinical proof of concept before out-licensing.

In addition to the proprietary projects, Karo Bio has three strategic
collaborations with international pharmaceutical companies for development of
innovative therapies for the treatment of common diseases.

Karo Bio is listed on the OMX Nordic Exchange Stockholm AB since 1998 (Reuters:
KARO.ST).

This press release is also available online at: www.karobio.com and
www.newsroom.cision.com